Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical’s Phase II clinical trial of the KRAS G12C inhibitor, garsorasib, has demonstrated promising results in treating non-small cell lung cancer with an objective response rate of 50% and a disease control rate of 89%. Published in The Lancet Respiratory Medicine, the study indicates garsorasib was well-tolerated, with a higher tumor response and longer duration of response among patients. This breakthrough has positioned garsorasib for priority review in China, with international trials underway for various cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
